Literature DB >> 15948121

The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries.

Victor E Gould1, Juan Miguel Mosquera, Kerstin Leykauf, Paolo Gattuso, Matthias Dürst, Angel Alonso.   

Abstract

We applied an antiserum (SA226P) specifically recognizing the phosphorylated form of connexin43 (P-Cx43) to human breast samples including normal breast samples, with fibrocystic disease (FCD), fibroadenomas (FA), in situ and infiltrating carcinomas of all major types, and miscellaneous extramammary tumors. The findings were compared with those obtained with commercial antisera recognizing all Cx43 forms (pan-Cx43). A subset of samples was stained for Her2-neu and p44/42 to mitogen-activated protein kinase. Paraffin step sections were used. Immunoblots were performed on frozen samples of a representative subset of cases. In the normal breast, FCD, and FA, SA226P stained strongly and extensively most myoepithelial cells (MECs); luminal cells remained unstained. In proliferative FCD and some cellular FA, SA226P stained MEC and the capillary endothelium (CE). In ductal and lobular in situ carcinomas, SA226P reacted strongly and diffusely with the remaining MEC, the CE, and the transformed luminal cells. SA226P stained all infiltrating carcinomas except the tubular variant. In all breast carcinomas, the CE within and adjacent to tumors and some myofibroblasts stained with SA226P. By contrast, pan-Cx43 stained weakly and sporadically the MEC and rare samples of invasive carcinomas. Notably, Mab p44/42 reacted in parallel with the samples stained with SA226P, whereas reactions with Her2 were negative. Immunoblot findings paralleled those obtained immunohistochemically. We conclude that P-Cx43, restricted to MEC in the normal breast, is up-regulated in the same cells in hyperplasias and dysplasias and FA and is strongly up-regulated in invasive carcinomas. Notably, in some proliferative FCD and in most in situ and infiltrating carcinomas, P-Cx43 is strongly expressed in CE within and adjacent to the lesions but not away from them. These findings were paralleled by the strong nuclear reactions noted with Mab p44/42. These phenomena, although not exclusive to malignancy, are particularly conspicuous in breast carcinomas and seemingly reflect active proliferation associated with abnormal gap junctional intercellular communication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948121     DOI: 10.1016/j.humpath.2005.03.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

Review 1.  Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues.

Authors:  Lucrecia Márquez-Rosado; Joell L Solan; Clarence A Dunn; Rachael P Norris; Paul D Lampe
Journal:  Biochim Biophys Acta       Date:  2011-07-26

2.  Pericytes on the tumor vasculature: jekyll or hyde?

Authors:  Keith D Barlow; Anne M Sanders; Shay Soker; Suleyman Ergun; Linda J Metheny-Barlow
Journal:  Cancer Microenviron       Date:  2012-03-31

Review 3.  Connexins and gap junctions in mammary gland development and breast cancer progression.

Authors:  Elizabeth McLachlan; Qing Shao; Dale W Laird
Journal:  J Membr Biol       Date:  2007-07-28       Impact factor: 1.843

4.  Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.

Authors:  Christina L Grek; Joshua Matthew Rhett; Jaclynn S Bruce; Melissa A Abt; Gautam S Ghatnekar; Elizabeth S Yeh
Journal:  BMC Cancer       Date:  2015-04-03       Impact factor: 4.430

5.  Tumor-induced loss of mural Connexin 43 gap junction activity promotes endothelial proliferation.

Authors:  Mayur Choudhary; Christine Naczki; Wenhong Chen; Keith D Barlow; L Douglas Case; Linda J Metheny-Barlow
Journal:  BMC Cancer       Date:  2015-05-23       Impact factor: 4.430

6.  Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration.

Authors:  Elizabeth S Yeh; Christina J Williams; Carly Bess Williams; Ingrid V Bonilla; Nancy Klauber-DeMore; Stephanie L Phillips
Journal:  Oncotarget       Date:  2017-11-25

Review 7.  The Complex Subtype-Dependent Role of Connexin 43 (GJA1) in Breast Cancer.

Authors:  Mélanie Busby; Michael T Hallett; Isabelle Plante
Journal:  Int J Mol Sci       Date:  2018-02-28       Impact factor: 5.923

Review 8.  Connexins and cAMP Cross-Talk in Cancer Progression and Metastasis.

Authors:  Chang-Xu Chen; Kai-Jun Luo; Jia-Peng Yang; Yun-Chao Huang; Eduardo R Cardenas; Bruce J Nicholson; Jean X Jiang
Journal:  Cancers (Basel)       Date:  2020-12-28       Impact factor: 6.639

Review 9.  Connexin 43 in the development and progression of breast cancer: What's the connection? (Review).

Authors:  Stephanie L Phillips; Carly Bess Williams; Joelle N Zambrano; Christina J Williams; Elizabeth S Yeh
Journal:  Int J Oncol       Date:  2017-09-01       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.